Drug manufacturer Lilly indicated late last week that it reserves the right to seek additional compensation for its products from 340B covered entities if it learns later that it charged them less than the 340B statute allows.
Drug manufacturer Lilly indicated late last week that it reserves the right to seek additional compensation for its products from 340B covered entities if it learns later that it charged them less than the 340B statute allows.
*Sign up for news summaries and alerts from 340B Report